Cinven acquires Theramex for €2.6bn as Carlyle and PAI secure exit
Wednesday, November 4, 2026 · first reported by Private Equity Wire and 1 other
Cinven has agreed to buy Theramex, a women's healthcare company based in London, from Carlyle and PAI Partners. The deal values the business at about €2.6bn, according to the Financial Times as relayed by Private Equity Wire. The sellers bought Theramex in 2022 for €1.4bn.
Theramex makes treatments for menopause, fertility, contraception and osteoporosis and operates in more than 80 countries. Cinven is said to plan further international expansion and product development.
- Firm
- Cinven
- Also named
- Carlyle, PAI Partners, Theramex
- Deal value
- $2.9B
- Asset class
- Private equity
- Geography
- Europe
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
Coverage
2 sources- EnCap explores $4bn-plus sale of US shale producer Enduring Resources IVPrivate Equity Wire
- Bridgepoint’s ECP to sell Harvestone to Andersons for $915mPrivate Equity Wire +1
- Japan fund JIC plans to sell JSR to Mitsui Chemicals, sources sayReuters +1
- Macquarie exits Mexican REIT after 14 years in $1.7bn takeoverAlternatives Watch
- Helen Of Troy Rejects $1.6B Empower Brands Buyout OfferLaw360
- Crane Completes Purchase of Trillium Pumps US from First Reserve-Backed TrilliumPrivate Equity Professional
Got news? Send it to us →